61.26
price down icon1.32%   -0.82
pre-market  Vorhandelsmarkt:  60.82   -0.44   -0.72%
loading
Schlusskurs vom Vortag:
$62.08
Offen:
$62.07
24-Stunden-Volumen:
1.57M
Relative Volume:
0.92
Marktkapitalisierung:
$12.15B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
437.57
EPS:
0.14
Netto-Cashflow:
$16.80M
1W Leistung:
+1.52%
1M Leistung:
-17.55%
6M Leistung:
-5.94%
1J Leistung:
+8.33%
1-Tages-Spanne:
Value
$60.81
$62.88
1-Wochen-Bereich:
Value
$60.21
$63.31
52-Wochen-Spanne:
Value
$50.35
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Firmenname
Incyte Corp
Name
Telefon
(302) 498-6700
Name
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Mitarbeiter
0
Name
Twitter
@Incyte
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
INCY's Discussions on Twitter

Vergleichen Sie INCY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INCY
Incyte Corp
61.26 12.15B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.28 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
640.14 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.66 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.21 34.84B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.92 27.23B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-18 Herabstufung Guggenheim Buy → Neutral
2025-03-18 Herabstufung William Blair Outperform → Mkt Perform
2024-12-17 Eingeleitet UBS Neutral
2024-10-29 Hochstufung BofA Securities Neutral → Buy
2024-10-01 Eingeleitet Wolfe Research Outperform
2024-09-18 Herabstufung Truist Buy → Hold
2024-07-02 Herabstufung BMO Capital Markets Market Perform → Underperform
2024-05-23 Eingeleitet Deutsche Bank Hold
2024-04-23 Eingeleitet Cantor Fitzgerald Neutral
2024-02-23 Eingeleitet Jefferies Buy
2024-02-14 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Hochstufung Leerink Partners Market Perform → Outperform
2023-12-04 Hochstufung Guggenheim Neutral → Buy
2023-11-21 Herabstufung Goldman Buy → Neutral
2023-07-25 Eingeleitet Citigroup Buy
2023-05-04 Herabstufung BofA Securities Buy → Neutral
2023-04-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Hochstufung SVB Securities Underperform → Market Perform
2023-01-31 Eingeleitet Piper Sandler Overweight
2022-08-03 Herabstufung Evercore ISI Outperform → In-line
2022-08-03 Herabstufung Guggenheim Buy → Neutral
2022-07-28 Eingeleitet Wells Fargo Equal Weight
2022-02-09 Herabstufung SVB Leerink Mkt Perform → Underperform
2022-01-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-07-20 Hochstufung The Benchmark Company Hold → Buy
2021-02-10 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-01-07 Eingeleitet Truist Buy
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-06-16 Eingeleitet The Benchmark Company Hold
2020-05-06 Herabstufung JP Morgan Overweight → Neutral
2020-04-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-24 Fortgesetzt William Blair Outperform
2020-03-13 Hochstufung BofA/Merrill Neutral → Buy
2020-02-04 Fortgesetzt BofA/Merrill Neutral
2020-01-03 Bestätigt BMO Capital Markets Market Perform
2020-01-03 Herabstufung Mizuho Buy → Neutral
2020-01-02 Herabstufung Guggenheim Buy → Neutral
2019-10-03 Eingeleitet Mizuho Buy
2019-09-12 Eingeleitet BMO Capital Markets Market Perform
2019-09-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Fortgesetzt Morgan Stanley Equal-Weight
2019-09-05 Hochstufung Oppenheimer Perform → Outperform
2019-05-21 Eingeleitet Credit Suisse Neutral
2019-05-03 Herabstufung Barclays Overweight → Equal Weight
2019-04-11 Eingeleitet Stifel Hold
2019-04-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Hochstufung William Blair Mkt Perform → Outperform
Alle ansehen

Incyte Corp Aktie (INCY) Neueste Nachrichten

pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - Marketscreener.com

Mar 24, 2025
pulisher
Mar 23, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 23, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte stock price target cut to $72 at Truist Securities - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte divulges new MRGPRX2 antagonists - BioWorld Online

Mar 18, 2025
pulisher
Mar 18, 2025

Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair cuts Incyte stock rating post-trial results - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim Downgrades Incyte to Neutral From Buy -March 18, 2025 at 06:41 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating -March 18, 2025 at 05:45 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (INCY) to Market Perform - StreetInsider.com

Mar 18, 2025
pulisher
Mar 17, 2025

Incyte stock dives after drug trial disappoints investors - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch

Mar 17, 2025
pulisher
Mar 17, 2025

RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Why Incyte (INCY) Stock Is Nosediving - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com

Mar 17, 2025
pulisher
Mar 17, 2025

US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock hit by 11% despite paediatric dermatology trials hitting target - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.

Mar 17, 2025
pulisher
Mar 17, 2025

Top Stock Movers Now: Intel, Netflix, Incyte, and More - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock decline after results an ‘overreaction,” says Wolfe Research - TipRanks

Mar 17, 2025

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$310.82
price down icon 1.87%
$76.57
price down icon 2.51%
$31.56
price down icon 6.52%
$19.89
price down icon 1.73%
$95.90
price down icon 1.18%
biotechnology ONC
$250.92
price up icon 0.18%
Kapitalisierung:     |  Volumen (24h):